These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9195604)

  • 1. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action.
    Mitchell IJ; Carroll CB
    Neurosci Biobehav Rev; 1997 Jul; 21(4):469-75. PubMed ID: 9195604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
    Carroll CB; Holloway V; Brotchie JM; Mitchell IJ
    Psychopharmacology (Berl); 1995 May; 119(1):55-65. PubMed ID: 7675950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset.
    Mitchell IJ; Hughes N; Carroll CB; Brotchie JM
    Behav Pharmacol; 1995 Aug; 6(5-6):492-507. PubMed ID: 11224357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
    Blanchet PJ; Papa SM; Metman LV; Mouradian MM; Chase TN
    Neurosci Biobehav Rev; 1997 Jul; 21(4):447-53. PubMed ID: 9195602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
    Nash JE; Hill MP; Brotchie JM
    Exp Neurol; 1999 Jan; 155(1):42-8. PubMed ID: 9918703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
    Crossman AR; Peggs D; Boyce S; Luquin MR; Sambrook MA
    Neuropharmacology; 1989 Nov; 28(11):1271-3. PubMed ID: 2687716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic drugs in Parkinson's disease.
    Lange KW; Riederer P
    Life Sci; 1994; 55(25-26):2067-75. PubMed ID: 7997066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism.
    Graham WC; Robertson RG; Sambrook MA; Crossman AR
    Life Sci; 1990; 47(18):PL91-7. PubMed ID: 2250573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
    Zhang C; Steiner JP; Hamilton GS; Hicks TP; Poulter MO
    J Neurosci; 2001 Aug; 21(15):RC156. PubMed ID: 11459877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
    Nash JE; Brotchie JM
    J Neurosci; 2000 Oct; 20(20):7782-9. PubMed ID: 11027242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
    Konieczny J; Ossowska K; Schulze G; Coper H; Wolfarth S
    Psychopharmacology (Berl); 1999 Apr; 143(3):235-43. PubMed ID: 10353425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism.
    Oueslati A; Breysse N; Amalric M; Kerkerian-Le Goff L; Salin P
    Eur J Neurosci; 2005 Dec; 22(11):2765-74. PubMed ID: 16324110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
    Karcz-Kubicha M; Lorenz B; Danysz W
    Neuropharmacology; 1999 Jan; 38(1):109-19. PubMed ID: 10193902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
    Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.